FDA 483 - The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories - March 20, 2026

The Harvard Drug Group LLC, operating as Major Pharmaceuticals and Rugby Laboratories in La Vergne, Tennessee, was issued an FDA 483 following an inspection from March 16 to March 20, 2026. The inspection, which evaluated the firm’s operations as a distributor and repackager, revealed significant lapses in quality oversight and regulatory compliance. One primary issue involved the quality control unit’s failure to implement written procedures for verifying critical label information, such as lot numbers and expiration dates, prior to shipping products. Additionally, investigators found that the company did not sufficiently expand its investigations into manufacturing defects. Despite receiving over 20 complaints regarding inadequate blister seals and initiating a recall for one lot, the firm failed to evaluate other products manufactured using the same defective processes and materials. Furthermore, the firm lacked robust systems to meet the requirements of the Drug Supply Chain Security Act (DSCSA). Specifically, their procedures were insufficient for identifying and investigating suspect products or responding to notifications about illegitimate goods. While these observations do not constitute a final agency determination, the company is expected to provide a formal response outlining its corrective actions or objections to the findings to ensure future compliance with safety and security standards.